Contact: Maureen Eister, room 9C–08, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301) 443–1340.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of activities in the fields of research and research training activities in the areas of clinical psychopathology and clinical biology as they relate to mental health, with recommendations to the National Advisory Mental Health Council for final review.

Committee name: Psychopathology Subcommittee of the Psychopathology and Clinical Biology Research Review Committee, NIMH.

Date and time: February 27–March 1: 9 a.m.

Place: Holiday Inn Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814.

Status of meeting: Open—February 27: 9–10 a.m. Closed—Otherwise.

Contact: Tammye Cross, room 9C–08, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301) 443–1340.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research and research training activities in the areas of clinical psychopathology and clinical biology as they relate to mental health, with recommendations to the National Advisory Mental Health Council for final review.

Committee name: Services Subcommittee on the Epidemiologic and Services Research Review Committee, NIMH.

Date and time: February 27–March 1: 9 a.m.

Place: Embassy Suites Hotel, 4300 Military Road, NW., Washington, DC 20015.

Status of meeting: OPEN—February 27: 9–10 a.m. CLOSED—Otherwise.

Contact: Gloria Yockelson, room 9C–05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301) 443–0948.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health for support of research and research training activities as they relate to mental health epidemiology, mental health service systems research, and evaluation of clinical mental health services, with recommendations to the National Advisory Mental Health Council for final review.

Committee name: Immunology and AIDS Subcommittee of the Alcohol Biomedical Research Review Committee, NIAAA.

Date and time: February 28–March 1: 9 a.m.

Place: Crowne Plaza Holiday Inn, 1750 Rockville Pike, Rockville, MD 20852.

Status of meeting: OPEN—February 28: 9–10 a.m. CLOSED—Otherwise.

Contact: Barbara Smothers, room 16C–26, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301) 443–6106.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute on Alcohol Abuse and Alcoholism for support of research and training activities, and makes recommendations to the National Advisory Council on Alcohol Abuse and Alcoholism for final review.

Committee name: Epidemiology Subcommittee of the Epidemiologic and Services Research Review Committee, NIMH.

Date and time: March 4–6: 9 a.m.

Place: Embassy Suites Hotel, 4300 Military Road, NW., Washington, DC 20015.

Status of meeting: OPEN—March 4: 9–10 a.m. CLOSED—Otherwise.

Contact: Gloria Yockelson, room 9C–05, Parklawn Building, 5600 Fishers Lane, Rockville, MD 20857 (301) 443–0948.

Purpose: The Subcommittee is charged with the initial review of applications for assistance from the National Institute of Mental Health of support of research and research training activities as they relate to mental health epidemiology, mental health service systems research, and evaluation of clinical mental health services, with recommendations to the National Advisory Mental Health Council for final review.

Substantive information, summaries of the meetings, and rosters of committee members may be obtained as follows: Ms. Diana Widner, NIAAA Committee Management Officer, room 16C–20, (301) 443–4375; Ms. Camille Holland, NIDA Committee Management Officer Room 10–42, (301) 443–2755; Ms. Joanna Kieffer, NIMH Committee Management Officer, room 9–105, (301) 443–4333. The mailing address for the above parties is: Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857.

Dated: January 7, 1991.

Peggy W. Cockrill,

Committee Management Officer, Alcohol, Drug Abuse, and Mental Health Administration.

[FR Doc. 91–629 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–20–M

Centers for Disease Control

Scientific Workshop on the Health Effects of Electromagnetic Radiation on Workers; Correction

This notice corrects the time and date of a previously announced meeting.

Federal Register Citation of Previous Announcement: December 14, 1990, 55 FR 51502.

Previously Announced Time and Date: 8 a.m.–12:30 p.m., January 31, 1991.

Correction: The correct times and dates are:

8 a.m.–5 p.m., January 30, 1991

8 a.m.–12:30 p.m., January 31, 1991.

Dated: January 7, 1991.

Glenda S. Cowart,

Director, Office of Program Support Centers for Disease Control.

[FR Doc. 91–665 Field 1–10–91; 8:45 am]

BILLING CODE 4160–19–M

FAMILY SUPPORT ADMINISTRATION

Forms Submitted to the Office of Management and Budget for Clearance

The Family Support Administration (FSA) will publish on Fridays information collection packages submitted to the Office of Management and Budget (OMB) for clearance, in compliance with the Paperwork Reduction Act (44 U.S.C. chapter 35). Following is the package submitted to OMB since the last publication.

(For a copy of the package, call the FSA, Report Clearance Officer 202–401–5604.)

Report of Claims of Good Cause for Refusing to Cooperate in Establishing Paternity and Securing Child Support—0970–0073—This information collection will be used to monitor administration of good cause and evaluate the extensiveness and reasons for usage. *Respondents:* State and local governments; *Number of respondents:* 54; *Frequency of response:* quarterly; *Estimated average burden per response:* 11.69; *Estimated annual burden:* 2,527 hours. *OMB desk officer:* Laura Oliven.

Written comments and recommendations for the proposed information collection should be sent directly to the OMB Desk Officer designated above at the following address: OMB Reports Management Branch, New Executive Office Building, room 3201, 725 17th Street, NW., Washington, DC 20503.

Dated: December 30, 1990.

Naomi B. Marr,

Associate Administrator, Office of Management and Information Systems.

[FR Doc. 91–639 Filed 1–10–91; 8:45 am]

BILLING CODE 4150–04–M

Food and Drug Administration

[Docket No. 91N–0005]

Animal Drug Export; Marinil (Metomidate Hydrochloride)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Wildlife Laboratories Inc., has filed an application requesting approval for export to Canada of the animal drug Marinil (metomidate hydrochloride).

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm.

4–62, 5600 Fishers Lane, Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of non-food animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person below.

FOR FURTHER INFORMATION CONTACT: Gregory S. Gates, Center for Veterinary Medicine (HFV–110), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3420.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the **Federal Register** within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Wildlife Laboratories Inc., 1401 Duff Dr., Suite 600, Fort Collins, CO 80524, has filed an application requesting approval for export to Canada of the animal drug Marinil (metomidate hydrochloride). The product is intended for use in sedation and anesthesia of non-food fish.

The application was received and filed in the Center for Veterinary Medicine on December 26, 1990, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by January 22, 1991, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.44).

Dated: January 4, 1991.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 91–637 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90D–0439]

Furazolidone and Nitrofurazone in Animal Feed; Compliance Policy Guide; Removal

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the removal of Compliance Policy Guide (CPG) 7125.13 "Furazolidone and Nitrofurazone in Animal Feed" on the ground that it has been superseded by current regulations.

FOR FURTHER INFORMATION CONTACT: Edward J. Ballitch, Center for Veterinary Medicine (HFV–230), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3336.

SUPPLEMENTARY INFORMATION: CPG 7125.12 "Furazolidone and Nitrofurazone in Animal Feed," was issued on October 1, 1980. The guide stated among other things that an approved medicated feed application (MFA) was not required for the manufacture of medicated feed containing either of these new animal drugs.

In the **Federal Register** of March 3, 1986 (51 FR 7382) FDA issued regulations which revised §§ 558.3 and 558.4 (21 CFR 558.3 and 558.4). These regulations require hat the manufacture of medicated feeds containing furazolidone or nitrofurazone be the subject of approved MFA's. Therefore, these regulations supersede the policy set forth in the guide, and the guide is hereby removed.

Dated: January 3, 1991.

Alan L. Hoeting,

Acting Associate Commissioner for Regulatory Affairs.

[FR Doc. 91–638 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90C–0453]

Teepak, Inc.; Filing of Color Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Teepak, Inc., has filed a petition proposing that the color additive regulations be amended to provide for the safe use of synthetic iron oxide for use in human food.

FOR FURTHER INFORMATION CONTACT: Rosalie M. Angeles, Center for Food Safety and Applied Nutrition (HFF–334), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–426–5487.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 706(d)(1) (21 U.S.C. 376(d)(1))), notice is given that Teepak, Inc., P.O. Box 11925, Columbia, SC 29211, has filed a petition (CAP OCO228) proposing that § 73.1200 *Synthetic iron oxide* (21 CFR 73.1200) of the color additive regulations be amended to provide for the safe use of synthetic iron oxide as a color additive in human food.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: December 28, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–636 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90F–0435]

Amoco Chemical Co.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Amoco Chemical Co. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of isobutylene-butene copolymers as components of food-

contact articles and as plasticizers in polypropylene in contact with food.

FOR FURTHER INFORMATION CONTACT: Julius Smith, Center for Food Safety and Applied Nutrition (HFF–335), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 1B4238) has been filed by Amoco Chemical Co., Chicago, IL 60601, proposing that § 177.1430 *Isobutylene-butene copolymers* (21 CFR 177.1430) be amended to provide for the safe use of isobutylene-butene copolymers as components of food-contact articles and as plasticizers in polypropylene in contact with food complying with 21 CFR 177.1520.

The potential environmental impact of this action is being reviewed. If the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: December 28, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–632 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90F–0414]

Kay-Ray/Sensall, Inc.; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Kay-Ray/Sensall, Inc., has filed a petition proposing that the food additive regulations be amended to provide for the safe use of an americium 241/beryllium neutron source for food inspection or to control food processing.

FOR FURTHER INFORMATION CONTACT: George H. Pauli, Center for Food Safety and Applied Nutrition (HFF–330), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5740.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP OM4202) has been filed by Kay-Ray/Sensall, Inc., 1400 Business Center Dr., Mt. Prospect, IL 60056. The petition proposes that § 179.21 (21 CFR 179.21) of the food additive regulations be amended to provided for the safe use of an americium 241/beryllium neutron source for food inspection or to control food processing.

The agency has carefully considered the potential environmental effects of this action. FDA has concluded that the action will not have a significant impact on the human environment, and that an environmental impact statement is not required. The agency's finding of no significant impact and the evidence supporting that finding, contained in an environmental assessment, may be seen in the Dockets Management Branch (HFA–305), Food and Drug Administration, Rm. 4–62, 5600 Fishers Lane, Rockville, MD 20857, between 9 a.m. and 4 p.m., Monday through Friday.

Dated: December 28, 1990.

Fred R. Shank,

Director, Center for Food Safety and Applied Nutrition.

[FR Doc. 91–635 Filed 1–10–91; 8:45 am]

BILLING CODE 4160–01–M

[Docket No. 90N–0407]

Revisions of Certain Food Chemicals Codex, 3D ed., Monographs; Opportunity for Public Comment

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing an opportunity for public comment on pending changes to certain Food Chemicals Codex, 3d Ed., monographs and is soliciting specification information on proposed new monographs. For certain substances used as food ingredients, revised materials consisting of new monographs, additions, changes, and corrections in several current monographs are being prepared by the National Academy of Sciences/Institute of Medicine (NAS/IOM) Committee on Food Chemicals Codex. These revised materials will be published in the third supplement to the Food Chemicals Codex, 3d Ed.

DATES: Comments by February 21, 1991. (The NAS/IOM Committee on Food Chemicals Codex advises that comments not received by this date cannot be considered for the third supplement but will be considered for later supplements.)

ADDRESSES: Written comments to the NAS/IOM Committee on Food Chemicals Codex, National Academy of Sciences, 2101 Constitution Ave. NW., Washington, DC 20418.

FOR FURTHER INFORMATION CONTACT:

Sanford W. Bigelow, Committee on Food Chemicals Codex, Food and Nutrition Board, National Academy of Sciences, 2101 Constitution Ave. NW., Washington, DC 20418, 202–334–2580.

or

Paul M. Kuznesof, Center for Food Safety and Applied Nutrition (HFF–415), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–472–5680.

SUPPLEMENTARY INFORMATION: FDA provides research contracts to the NAS/IOM to support preparation of the Food Chemicals Codex, a compilation of specifications for substances used as food ingredients. In the **Federal Register** of January 26, 1984 (49 FR 3271), the FDA announced that the NAS/National Research Council Committee on Food Chemicals Codex was considering monographs and revisions for inclusion in the second supplement to the Food Chemicals Codex, 3d Ed., which has since been published. The public was invited to comment and to make suggestions for consideration and inclusion in that publication.

The agency now gives notice that the NAS/IOM Committee on Food Chemicals Codex is soliciting comments and information on proposed new monographs and proposed changes to certain current monographs. Information received in response to this notice will be used to develop these new monographs and for determining the necessity of making the contemplated changes to the current monographs. These changes and new monographs will be published in the third supplement to the Food Chemicals Codex, 3d Ed. Copies of the proposed changes to current monographs may be obtained from The National Academy of Sciences (NAS) at the address listed above.

FDA emphasizes, however, that it will not consider adopting any new monographs or revisions published in the third supplement to the Food Chemicals Codex, 3d Ed., until the public has had ample opportunity to comment on the changes to existing monographs and the new monographs. The opportunity for public comment on the adoption of new monographs or revisions published in the third supplement will be the subject of a separate notice published in the **Federal Register.**

The NAS/IOM Committee on Food Chemicals Codex invites comments and suggestions of specifications by all